-
Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer
22 May 2025 21:03 GMT
… MYTX-011, in patients with non-small cell lung cancer (NSCLC) at the 2025 American Society … with previously treated, advanced NSCLC: Updated dose escalation results … locally advanced, recurrent or metastatic NSCLC (NCT05652868).
About Mythic Therapeutics
…
-
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
22 May 2025 11:20 GMT
… for patients with advanced non-small cell lung cancer (NSCLC) with a 48-hour … enabling comprehensive biomarker profiling for NSCLC.”
Key features of NeoGenomics’ … MET protein overexpression.
Integrated NSCLC Offering: Complements NeoGenomics’ broader …
-
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting
21 May 2025 20:28 GMT
… ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), will be presented … patients with ROS1-positive non-small cell lung cancer,” said David Hung … taletrectinib for advanced ROS1+ NSCLC (line agnostic, full … with ROS1+ NSCLC and other NSCLC indications. In …
-
NeoGenomics introduces c-MET companion diagnostic for NSCLC
23 May 2025 22:06 GMT
… Diagnostic (CDx) for use in non-small cell lung cancer (NSCLC), offering a 48-hour turnaround … of the company’s extensive NSCLC testing offerings, supporting the adoption … , enabling comprehensive biomarker profiling for NSCLC.”
In October 2024, the company …
-
Pulsed Electric Field Ablation May Show Feasibility, Safety in Early NSCLC
23 May 2025 18:30 GMT
… –small cell lung cancer (NSCLC), according to findings from … event for early-stage NSCLC,” lead study author Marcelo … or confirmed early-stage NSCLC across 4 trial sites … the treatment of early stage non-small cell lung cancer (INCITE ES). ClinicalTrials.gov. …
-
Infusion-Related Reactions: Clinical Trials and Guideline-Driven Prophylaxis and Management Strategies for Patients Undergoing NSCLC Treatment
23 May 2025 18:03 GMT
A panelist discusses how clinical trials and institutional guidelines have improved the management of infusion-related reactions (IRRs) through standardized premedication protocols, including the SKIPPirr trial, which demonstrated that home dexamethasone …
-
Infusion Hesitancy and the Impact of Route of Administration of NSCLC Treatment Options in Patients’ Quality of Life
23 May 2025 18:03 GMT
A panelist discusses how evidence-based protocols for managing infusion-related reactions have reduced hesitancy among health care providers to use agents like amivantamab, empowered the entire care team with knowledge, and balanced the benefits and …
-
New Study Published on the Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection
20 May 2025 16:14 GMT
… anesthetic event for early-stage NSCLC."
The multi-center … with suspected or confirmed NSCLC stage IA2-IB across … evaluating aPEF in late-stage NSCLC, lung metastases, and … Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection. …
-
Early NSCLC at ASCO: Evaluating New Assay & Treatment Patterns
23 May 2025 01:04 GMT
… including several abstracts on early non-small cell lung cancer (eNSCLC).
Presurgical Prognostication
The … patients with stage I–IIIA NSCLC, collecting pretreatment plasma samples … prognostic indicator in early-stage NSCLC,” the study authors concluded. …
-
Discontinuation Did Not Reduce CheckMate 9LA Regimen’s Efficacy in NSCLC
23 May 2025 01:43 GMT
About
© 1995-2025